BioCentury | Dec 31, 2016
Finance

Delivering takeouts

BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are looking...
BioCentury | Mar 28, 2016
Clinical News

Anthim obiltoxaximab regulatory update

...FDA approved a BLA from Elusys for Anthim obiltoxaximab to treat inhalational anthrax in combination with...
...The high-affinity humanized mAb against the Bacillus anthracis protective antigen inhibits binding of anthrax toxins. Elusys Therapeutics Inc....
BioCentury | Mar 22, 2016
Company News

FDA approves Elusys' Anthim for inhalational anthrax

...FDA approved Anthim obiltoxaximab from Elusys Therapeutics Inc. (Pine Brook, N.J.) to treat inhalational anthrax in combination with...
BioCentury | Nov 16, 2015
Company News

Elusys, Department of Health and Human Services infectious news

...high-affinity humanized mAb against the Bacillus anthracis protective antigen that inhibits binding of anthrax toxins. Elusys Therapeutics Inc....
BioCentury | Nov 13, 2015
Company News

Elusys gets $44.9M BARDA order

Elusys Therapeutics Inc. (Pine Brook, N.J.) said it received a $44.9 million order for investigational anthrax therapy Anthim obiltoxaximab from the Biomedical Advanced Research and Development Authority for the U.S. Strategic National Stockpile. A BLA...
BioCentury | Jun 15, 2015
Clinical News

Anthim obiltoxaximab regulatory update

...FDA accepted a BLA for Anthim obiltoxaximab from Elusys to treat and prevent inhalational anthrax. The...
...Development Authority (BARDA) (see BioCentury, Aug. 9, 2010; Sept. 12, 2011 & Sept. 24, 2012). Elusys Therapeutics Inc....
BioCentury | Oct 13, 2014
Clinical News

Anthim obiltoxaximab: Phase III data

...were pruritus and headache. The most common hypersensitivity events reported were pruritus, rash and urticaria. Elusys...
...Development Authority (BARDA) (see BioCentury, Aug. 9, 2010; Sept. 12, 2011 & Sept. 24, 2012). Elusys Therapeutics Inc....
BioCentury | Oct 13, 2014
Clinical News

Anthim obiltoxaximab: Phase III data

...to obiltoxaximab reported was urticaria and no serious adverse events related to obiltoxaximab were reported. Elusys...
...Development Authority (BARDA) (see BioCentury, Aug. 9, 2010; Sept. 12, 2011 & Sept. 24, 2012). Elusys Therapeutics Inc....
BioCentury | Oct 13, 2014
Clinical News

Anthim obiltoxaximab: Phase III data

...swelling, infusion-site erythema and infusion-site pain. No serious adverse events related to obiltoxaximab were reported. Elusys...
...Development Authority (BARDA) (see BioCentury, Aug. 9, 2010; Sept. 12, 2011 & Sept. 24, 2012). Elusys Therapeutics Inc....
BioCentury | Apr 14, 2014
Company News

Elusys management update

Elusys Therapeutics Inc. , Pine Brook, N.J. Business: Antibodies, Infectious, Autoimmune Hired: Lawrence Gyenes as CFO, formerly CFO of Columbia Laboratories Inc. WIR Staff autoimmune Infectious...
Items per page:
1 - 10 of 87
BioCentury | Dec 31, 2016
Finance

Delivering takeouts

BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are looking...
BioCentury | Mar 28, 2016
Clinical News

Anthim obiltoxaximab regulatory update

...FDA approved a BLA from Elusys for Anthim obiltoxaximab to treat inhalational anthrax in combination with...
...The high-affinity humanized mAb against the Bacillus anthracis protective antigen inhibits binding of anthrax toxins. Elusys Therapeutics Inc....
BioCentury | Mar 22, 2016
Company News

FDA approves Elusys' Anthim for inhalational anthrax

...FDA approved Anthim obiltoxaximab from Elusys Therapeutics Inc. (Pine Brook, N.J.) to treat inhalational anthrax in combination with...
BioCentury | Nov 16, 2015
Company News

Elusys, Department of Health and Human Services infectious news

...high-affinity humanized mAb against the Bacillus anthracis protective antigen that inhibits binding of anthrax toxins. Elusys Therapeutics Inc....
BioCentury | Nov 13, 2015
Company News

Elusys gets $44.9M BARDA order

Elusys Therapeutics Inc. (Pine Brook, N.J.) said it received a $44.9 million order for investigational anthrax therapy Anthim obiltoxaximab from the Biomedical Advanced Research and Development Authority for the U.S. Strategic National Stockpile. A BLA...
BioCentury | Jun 15, 2015
Clinical News

Anthim obiltoxaximab regulatory update

...FDA accepted a BLA for Anthim obiltoxaximab from Elusys to treat and prevent inhalational anthrax. The...
...Development Authority (BARDA) (see BioCentury, Aug. 9, 2010; Sept. 12, 2011 & Sept. 24, 2012). Elusys Therapeutics Inc....
BioCentury | Oct 13, 2014
Clinical News

Anthim obiltoxaximab: Phase III data

...were pruritus and headache. The most common hypersensitivity events reported were pruritus, rash and urticaria. Elusys...
...Development Authority (BARDA) (see BioCentury, Aug. 9, 2010; Sept. 12, 2011 & Sept. 24, 2012). Elusys Therapeutics Inc....
BioCentury | Oct 13, 2014
Clinical News

Anthim obiltoxaximab: Phase III data

...to obiltoxaximab reported was urticaria and no serious adverse events related to obiltoxaximab were reported. Elusys...
...Development Authority (BARDA) (see BioCentury, Aug. 9, 2010; Sept. 12, 2011 & Sept. 24, 2012). Elusys Therapeutics Inc....
BioCentury | Oct 13, 2014
Clinical News

Anthim obiltoxaximab: Phase III data

...swelling, infusion-site erythema and infusion-site pain. No serious adverse events related to obiltoxaximab were reported. Elusys...
...Development Authority (BARDA) (see BioCentury, Aug. 9, 2010; Sept. 12, 2011 & Sept. 24, 2012). Elusys Therapeutics Inc....
BioCentury | Apr 14, 2014
Company News

Elusys management update

Elusys Therapeutics Inc. , Pine Brook, N.J. Business: Antibodies, Infectious, Autoimmune Hired: Lawrence Gyenes as CFO, formerly CFO of Columbia Laboratories Inc. WIR Staff autoimmune Infectious...
Items per page:
1 - 10 of 87